Biotech Values

[dewophile]

The OS curves must cross bc HR less than one while median Numerically worse. So perhaps the farther out you go you start to see incremental OS benefit for the drug? Anyway unless you have another selling point like tolerability advantage or some benefit in clearly defined subgroup hard to see oncologists lining up to prescribe it for small PFS benefit and equal OS